Nicholas A Pomato, 791809 Millstream Dr, Frederick, MD 21702

7628996, Dec 8, 2009

Feb 21, 2003

10/370081

Martin V. Haspel - Seneca MD, US
Nicholas Pomato - Frederick MD, US

Intracel Resources LLC - Frederick MD

A61K 35/12

4242771

This invention relates to methods of removing bioburden from an aggregate of cells to obtain sterile cells that remain viable and immunogenic for the production of vaccines. This invention further relates to a method of eliciting an immune response to prevent a recurrence of metastases that involves preparing and administering a sterile vaccine derived from solid tumors. The vaccine is prepared by excising a solid tumor from a cancer patient, digesting the tumor cells with an enzyme to obtain dissociated cells, irradiating the dissociated cells to render the cells non-tumorigenic, and sterilizing the cells.

8343508, Jan 1, 2013

Dec 11, 2009

12/636315

Nicholas Pomato - Frederick MD, US
Martin V. Haspel - Seneca MD, US
Janet H. Ransom - North Potomac MD, US

Intracel Holdings LLC - Frederick MD

A61K 39/08
A61K 45/00
A61K 39/00
A61K 39/02

4242391, 4242781, 4241841, 4242361, 4242471

This invention provides antitoxin compositions and methods of production, and methods of treating animals and humans prophylactically and also those suspected of having contacted botulism toxin. The antitoxin is prepared by inoculating an animal with a monovalent toxoid and toxin. The animal's plasma is collected and purified at a high pH by affinity chromatography. The resulting monovalent immunoglobulins are de-speciated by digestion with pepsin. Monovalent antitoxins for all seven serotypes are then combined to produce a high titered heptavalent antitoxin composition.

2005004, Feb 24, 2005

May 19, 2004

10/848364

Nicholas Pomato - Frederick MD, US
Martin Haspel - Seneca MD, US
Janet Ransom - North Potomac MD, US

A61K039/08
G01N033/53

436547000

This invention provides antitoxin compositions and methods of production, and methods of treating animals and humans prophylactically and also those suspected of having contacted botulism toxin. The antitoxin is prepared by inoculating an animal with a monovalent toxoid and toxin. The animal's plasma is collected and purified at a high pH by affinity chromatography. The resulting monovalent immunoglobulins are de-speciated by digestion with pepsin. Monovalent antitoxins for all seven serotypes are then combined to produce a high titered heptavalent antitoxin composition.

5338832, Aug 16, 1994

Aug 13, 1992

7/929842

Nicholas Pomato - Frederick MD
Ebo S. Bos - De Veiesstratt, NL
Martin V. Haspel - Silver Spring MD
Michael G. Hanna - Frederick MD
Michael L. Berman - Potomac MD

Akzo N.V. - Velperweg

C07K 1300
C07K 500
C07K 1528

530350

The present invention comprises the epitope recognized by the human monoclonal antibody 16-18, the human tumor antigen containing this epitope, which we have identified, isolated and characterized, and anti-idiotypic antibodies to human MCA 16-88, which comprise the same epitope. The invention also relates to the use of antibodies to the antigen containing this epitope for diagnosis and monitoring of treatment of cancer and to the use of this antigen in the preparation of vaccines to elicit an immune response similar to that obtained against tumor cells containing this epitope.

5705634, Jan 6, 1998

Mar 2, 1995

8/397464

Reinhard Bredehorst - Hamburg, DE
Nicholas Pomato - Frederick MD
Oliver Scheel - Pinneberg, DE
Joachim Thiem - Hamburg, DE

PerImmune Holdings, Inc. - Rockville MD

C08B 3708
C08B 3700

536124

The present invention is directed to a new process for the production of chitin oligomers, including fragmentation, partial hydrolysis and recovery. This process produces high yields, especially of higher (tetra- to deca-) chitin oligomers.

5595738, Jan 21, 1997

Dec 6, 1993

8/150036

Nicholas Pomato - Frederick MD
Janet H. Ransom - Shepardstown WV

Akzo Nobel N.V. - Arnhem

A61K 3120
A61K 3438

4241841

A lipid antigen found in colon, breast, lung, ovarian and pancreatic human adenocarcinomas identified by reactivity with human monoclonal antibody 81AV78, and the use of the antigen in vaccines.

5965106, Oct 12, 1999

Jun 5, 1995

8/461267

Nicholas Pomato - Frederick MD
Richard P. McCabe - West Chester PA
Gregory A. Hawkins - Madison WI
Reinhard Bredehorst - Hamburg, DE
Chong-Ho Kim - Rockville MD
Carl-Wilhelm Vogel - Hamburg, DE

PerImmune Holdings, Inc. - Rockville MD

A61K 39395
A61K 5100
A61K 5110

424 153

A method for in-vivo targeting a functional moiety in a patient by administering a targeting moiety coupled to an affinity component, wherein the targeting moiety has affinity for binding sites in a target area, and administering a binding partner to the affinity component coupled to a functional moiety to localize the functional moiety in the target area. Preferably the targeting moiety is an antibody and the functional moiety is a radiometal when performing in vivo imaging or therapy. The affinity component may be a novel methotrexate analog. Preferably, the affinity component is thermo-stabilized.

5433955, Jul 18, 1995

Oct 8, 1993

8/134520

Reinhard Bredehorst - Washington DC
Chong-Ho Kim - Rockville MD
Richard McCabe - Rockville MD
Nicholas Pomato - Frederick MD
Carl-Wilhelm Vogel - Washington DC

Akzo N.V. - Arnhem

A61K 3758
A61K 3170
C12N 1106
C07H 15252

424 943

A method for site-specific in-vivo activation of a prodrug in an animal using an activator-targeting moiety conjugate to localize an activator at a predetermined site of use and a prodrug compound that is converted to an active drug in the presence of the activator. In the preferred embodiment, the targeting moiety, the activator, and the prodrug demonstrate little or no immunogenicity in the animal being treated. The targeting moiety is relatively specific for binding to the target tissue than to non-target tissue. The activator is not found or present in only small amounts in circulation or in non-target tissue, does not have a substrate for its activity in circulation or in non-target tissue, can be linked to the targeting moiety, and is capable of converting the prodrug to an active drug. The prodrug is selected for its ability to exert a cytotoxic activity on the target tissue after conversion by the activator.